1 The 1-adrenoceptor agonist, isoprenaline (1.5-3.0 mg kg-intravenously), produced a doserelated increase in rat pineal melatonin content. This increase was prevented by pretreatment with the selective PI-adrenoceptor antagonist, atenolol (2mgkg 1), but not by the P2-adrenoceptor antagonist, butoxamine (2 mg kg-1). The P2-adrenoceptor agonist, terbutaline (5.0mg kg-1), produced a moderate increase in pineal melatonin content. 2 Repeated daily administration of desmethylimipramine (10mg kg-for 10 days) and maprotiline (10mg kg-for 10 days), antidepressants predominantly inhibiting noradrenaline (NA) uptake, reduced the isoprenaline-induced increase in pineal melatonin content. Amitriptyline (20 mg kg-I for 14 days), a drug which inhibits both NA and 5-hydroxytryptamine (5-HT) uptake, had a similar effect. The P-adrenoceptor agonist, clenbuterol (5 mg kg-for 14 days), also attenuated the increase in pineal melatonin produced by isoprenaline. 3 In contrast, chronic administration of the selective 5-HT uptake inhibitor, fluoxetine (10mg kg-for 10 days), or the antidepressants, iprindole and mianserin (both 20mg kg1 for 14 days), which do not inhibit monoamine uptake, failed to reduce the increase in pineal melatonin following isoprenaline. Repeated electroconvulsive shock was similarly without effect. 4 Ten hours after the final dose of desmethylimipramine (10mg kg-1) once daily for 10 days there was no change in the usual dark phase increase in pineal melatonin. 5 The data suggest that repeated administration of certain antidepressant drugs results in reduced pineal P-adrenoceptor sensitivity. However the lack of change in the dark phase increase in pineal melatonin following repeated desmethylimipramine, implies that the reduced B-adrenoceptor sensitivity may be part of an adaptive process which maintains normal pineal function. Therefore the decrease in 1-adrenoceptor number in the brain reported after chronic antidepressant administration may not be associated with a change in overall synaptic function.
Introduction
Recent research on the pharmacological effects of antidepressant drugs has focused on the adaptive changes produced by these compounds on central monoamine mechanisms. In particular it has been shown that many different antidepressant treatments, including repeated electroconvulsive shock (ECS), reduce P-adrenoceptor binding in certain regions of rat brain (Bergstrom & Kellar, 1979; Pandey, Heinze, Brown & Davis, 1979; Sellinger-Barnette, Mendels & Frazer, 1980) . The reduction in 1-adrenoceptor ligand binding is often, but not invariably (Mishra, Janowsky & Sulser, 1980) , associated with a reduction in the responsiveness of noradrenaline-sensitive adenylate cyclase (Vetulani & Sulser, 1975; Wolfe, Harden, Sporn & Molinoff, 1978) .
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In order to demonstrate the consequences in vivo of longer term antidepressant administration on Padrenoceptor sensitivity, we have measured the melatonin content of rat pineal gland since the production of melatonin is dependent on P-adrenoceptor stimulation (Axelrod, 1974) . While the pineal gland may have direct neural connection with the brain (Dafny, 1980) , its noradrenergic innervation is supplied by postganglionic sympathetic fibres whose cell bodies lie in the superior cervical ganglia (Moore, 1978) . Experiments in vitro have demonstrated that adrenoceptor binding and on cortical Padrenoceptors (Moyer, Greenberg, Frazer, Brunswick, Mendels & Weiss, 1979) .
To assess whether any particular pharmacological action of antidepressants could be linked with an effect on pineal P-adrenoceptors, we tested a number of antidepressant treatments which differ in their effect on monoamine uptake (see Iversen & Mackay, 1979) . Of the tricyclic antidepressants tested, DMI inhibits the uptake of NA with a ten fold greater potency than that of 5-HT (Waldmeier, Greengrass, Baumann & Maitre, 1976) , while amitriptyline is about equipotent in its inhibitory effect on 5-HT and NA uptake (Waldmeier et al., 1976) . The tetracyclic compound, maprotiline, potently inhibits NA uptake but has only a very weak effect on 5-HT uptake (Maitre, Greengrass, Jackel, Sedlacek & DeliniStula, 1975) . In contrast, fluoxetine inhibits 5-HT uptake, but has a negligible effect on uptake into catecholamine neurones (Fuller & Wong, 1977) . The tricyclic antidepressant, iprindole, does not appear to block monoamine uptake to any great extent (Rosloff & Davis, 1974) and the tetracyclic antidepressant, mianserin, similarly has a weak effect on this process (Baumann & Maitre, 1977 ). In addition we tested the effect of the lipophilic P-adrenoceptor agonist, clenbuterol (Engelhardt, 1976) since Padrenoceptor agonists are currently being evaluated as antidepressants.
Repeated administration of all these treatments except for flouoxetine (Peroutka & Snyder, 1980) and mianserin (Sellinger-Barnette et al., 1980; Mishra et al., 1980) reduce cortical P-adrenoceptor binding (Sellinger-Barnette et al., 1980; Hall, Sallemark & Ross, 1980) . The effect of maprotiline on brain P-adrenoceptor binding has not been described. A preliminary account of some of this work has been presented to the British Pharmacological Society (Cowen & Fraser, 1981 (Romero, Zatz, Kebabian & Axelrod, 1975) (Arendt, Paunier & Sizonenko, 1975; Arendt & Wilkinson, 1979 (Lowry, Rosebrough, Farr & Randall, 1951 The following drugs were kindly donated by the Companies concerned: amitriptyline (Roche), atenolol (ICI Pharmaceuticals), butoxamine (Burroughs Wellcome), clenbuterol (BoehringerIngelheim), DMI and maprotiline (Ciba-Geigy), fluoxetine (Eli Lilly), iprindole (Wyeth Laboratories) and mianserin (Organon).
All these drugs were dissolved in saline except for maprotiline, which was dissolved in distilled water.
Administration of drugs and electroconvulsive shock (ECS)
Isoprenaline and terbutaline were administered i.v. via a tail vein. All other drugs were given intraperitoneally (i.p.). Chronically administered drugs were injected at a dose of 10mgkg-' either once daily at 14h 00min (DMI, maprotiline and fluoxetine) or twice daily at 09 h 00 min and 18 h 00 min (amitriptyline, mianserin, iprindole). Clenbuterol was injected once daily at a dose of 5.0mgkg-. Isoprenaline testing was carried out as described on the day following the final injection.
ECS (125 V, 50 Hz sinusoidal for 1 s) was given via earclip electrodes once daily at 14 h 00 min for 10 days. A grand mal seizure was always observed. Control animals were similarly handled, electrodes placed but no current passed ('handled'). Isoprenaline testing was carried out the next day.
Statistics
Differences between control and experimental groups of animals were analysed by Student's unpaired ttest (two-tailed). 
Results
Effectofisoprenaline on the synthesis ofmelatonin by thepineal gland An i.v. injection of 0.9% w/v NaCl solution (saline) or vehicle (see Methods) at 11 h 00 min had no effect on the concentration of melatonin in the pineal. Isoprenaline produced a dose-related increase in pineal melatonin content 3 h later (Figure 1 ). Effect ofrepeated administration ofantidepressant drugs, a Pf-adrenoceptoragonist and ECS on the isoprenaline-induced increase in pineal melatonin
In animals given a saline injection once daily for 10 days, isoprenaline (1.5mgkg-1) produced an increase in pineal melatonin concentration 24 h after the last injection (Table 2) .
When rats were given saline once daily for 9 days followed by DMI (10mg kg-1) on day 10, there was no significant alteration in the isoprenaline stimulation of pineal melatonin content 24 h later. However, 24 h after the final dose of DMI (10 mg kg-') given once daily for 10 days, the isoprenaline-induced melatonin rise was abolished. In addition, the basal melatonin concentration was decreased (Table 2) .
Another relatively selective NA uptake inhibitor, maprotiline (10mg kg-for 10 days), also reduced both the basal melatonin level and the increase in melatonin following isoprenaline (Table 2) . Amitriptyline (10mgkg-1 twice daily for 14 days) which inhibits both NA and 5-HT uptake did not decrease the basal melatonin concentration but did produce a moderate reduction in the pineal response to isoprenaline (Table 2 ). In contrast, 14 days' treatment with the antidepressants, mianserin and iprindole (both 10mgkg-1 twice daily), did not reduce either the basal melatonin concentration or the response to isoprenaline ( Table 2) . Neither of these drugs inhibits monoamine uptake (see Discussion).
When the specific 5-HT uptake inhibitor, fluoxetine (10mgkg-1) was administered for 10 days there was no effect on basal melatonin concentration or the isoprenaline-induced melatonin increase.
However, treatment with the P-adrenoceptor agonist, clenbuterol (5 mg kg-1), for 14 days, whilst not (Table 2) . Finally, repeated electroconvulsive shock was found to have no effect on either the basal melatonin content or the isoprenaline-induced rise.
Effect of repeated desmethylimipramine administration on the night-time rise inpineal melatonin concentration At midnight, 10 h after the last of 10 once daily saline injections, animals showed the usual marked nocturnal rise in pineal melatonin content (Arendt, Ho, Laud, Marston, Nohria, Smith & Symons, 1981 (Table 3) .
Discussion
The pineal enzyme, serotonin (5-HT) Nacetyltransferase (SNAT), catalyses a critical regulatory step in the formation of melatonin (Axelrod, 1974) . SNAT is synthesized in a dose-dependent manner following administration of the Padrenoceptor agonist, isoprenaline (Axelrod, 1974) .
Our results show that the increase in pineal melatonin following isoprenaline is also dose-dependent and that the increase is prevented by the Piadrenoceptor antagonist, atenolol, but not by the P2-adrenoceptor antagonist, butoxamine. The P2-adrenoceptor agonist, terbutaline, at a dose of 5 mg kg 1, did produce a modest increase in pineal melatonin content. This finding is consistent with previous experiments in vitro which demonstrated that while terbutaline has agonist activity at pineal 3-adrenoceptors, its affinity is less than that of a selective 1l3-adrenoceptor agonist (Backstr6m, 1977) . Pineal P-adrenoceptors have characteristics in vitro of the PI-subtype (Zatz etal., 1976) ; however, it appears, in common with certain other Pladrenoceptors (Lecler, Rouot, Schwartz & Vetty, 1981) , that they respond to P2-adrenoceptor agonists if a sufficient dose is administered. Overall, therefore, our observations are in accord with the in vitro data. Atenolol crosses the blood-brain barrier poorly (Day, Hemsworth & Street, 1977) and its blockade of the isoprenaline-induced increase in melatonin content is consistent with evidence suggesting that the pineal gland lies outside the blood-brain barrier (Arendt et al., 1981) . The effectiveness of isoprenaline in increasing melatonin is also in keeping with this interpretation. It has been reported that various stresses, including saline injection, can increase pineal melatonin levels (Lynch, Wang & Wurtman, 1973; Lynch, Eng & Wurtman, 1973) , but in our studies administration of either i.v. saline or vehicle was without such effect.
Many antidepressant treatments, when administered for periods similar to those required to produce a clinical antidepressant effect, cause a reduction in the number of P-adrenoceptor binding sites (see In- troduction). This change in general correlates with the ability of the drugs to inhibit NA uptake. Downregulation in postsynaptic P-adrenoceptor number is thought to be an adaptive change to the increase in synaptic cleft concentration of noradrenaline (see Green & Nutt, 1982) . However, inhibition of NA uptake is not the only mechanism involved in Padrenoceptor down-regulation. Iprindole, a tricyclic antidepressant, does not appear to block monoamine uptake (Rosloff & Davis, 1974; Iversen & Mackay, 1979) ; nevertheless it reduces cortical P- (4) ECS and DMI were administered once daily for 10 days (x 10). Pineals were removed 24 h after the last treatment and binding performed as described in Methods. Figures in parentheses are number of binding samples. Each sample consisted of three pineals. Values are mean ± s.e.mean. adrenoceptor binding (Wolfe et al., 1978) . In addition, there is evidence that the P-adrenoceptor agonist, clenbuterol, also down-regulates central Padrenoceptors (Hall, et al., 1980) and this is presumably a consequence of chronic agonist stimulation.
The synthesis of melatonin by the pineal gland in response to isoprenaline challenge provides a functional index of P-adrenoceptor sensitivity (Axelrod, 1974) and we have used this model to investigate the effects of various antidepressants on P-adrenoceptor function. Previous reports have indicated that repeated DMI administration reduces both pineal f3-adrenoceptor binding and the maximum cyclic AMP response to noradrenaline and isoprenaline (Moyer et al., 1979) . Our results show that following 10 days DMI administration there is an attenuation of the isoprenaline-induced increase in pineal melatonin content, suggesting a decreased sensitivity of the pineal to P-adrenoceptor stimulation. Similarly, the reduction in pineal isoprenaline response following repeated amitriptyline and clenbuterol, is consistent with the reported effects of these drugs on cortical 1-adrenoceptor binding (Sellinger-Barnette et al., 1980; Hall et al., 1980) although there is no information about their effect on pineal P-adrenoceptor binding. We have been unable to find data on the effect of the tetracyclic antidepressant, maprotiline on cortical P-adrenoceptor binding. However, a reduction in receptor density following chronic administration of this drug might be expected since it is a potent noradrenaline uptake inhibitor (Iversen & Mackay, 1979) , and as shown here, reduces the pineal response to isoprenaline.
In the animals treated with DMI and maprotiline, interpretation of the reduced isoprenaline response is complicated by the lower basal levels of melatonin in the animals given i.v. vehicle. However, the percentage increase in pineal melatonin in the maprotilinetreated animals following isoprenaline is less than that of controls and in the case of DMI there is no significant increase at all following isoprenaline. This suggests that as well as lowering basal levels of melatonin, repeated DM1 and maprotiline do reduce the pineal P-adrenoceptor response to isoprenaline.
However, chronic DMI did not significantly alter the usual dark phase increase in pineal melatonin, suggesting that the decrease in P-adrenoceptor sensitivity may be part of an adaptive response which maintains normal pineal function during repeated DMI administration. In contrast to certain electrophysiological investigations (Huang, Maas & Hu, 1980) , behavioural studies have suggested that a reduction in noradrenergic function is not seen during a course of DMI treatment, but rather, during the withdrawal period Willner, Montgomery & Bird, 1981 (Kafka, Wirz-Justice & Naber, 1981) . If, however, the P-adrenoceptor down-regulation in the pineal following antidepressants does not alter the overall function of pineal NA synapses then it suggests that care should be taken in attributing importance to the process of P-adrenoceptor downregulation as part of the therapeutic mechanism of antidepressant drugs (e.g. Sulser, 1979) .
Mianserin has little effect on monoamine uptake and although it has been reported to block M2-adrenoceptors when given acutely, this effect is not seen following longer term administration (see Green & Nutt, 1982) . Repeated administration of mianserin does not produce a reduction in cortical P-adrenoceptor binding, even after long-term treatment at high dose (Sellinger-Barnette et al., 1980; Mishra et al., 1980) .
The selective 5-HT inhibitor, fluoxetine, similarly does not change cortical ,B-adrenoceptor binding (Peroutka & Snyder, 1980) . Chronic administration of these drugs did not change the pineal response to isoprenaline which is in accord with their lack of effect on cortical P-adrenoceptor binding. In contrast, it has been reported that repeated ECS reduces cortical 1-adrenoceptor binding (Pandey etal., 1979) but this treatment failed to alter the pineal response to isoprenaline in the present experiments. However, the effect of repeated ECS on brain P-adrenoceptor binding shows regional specificity (Stanford & Nutt, 1982) and our binding data suggest that repeated ECS does not alter pineal P-adrenoceptor density.
The results of the binding data following repeated DMI were less conclusive, although the percentage decrease in P-adrenoceptor binding in the pineal was similar to that seen in rat cortex following the same DMI regimen (Stanford, Nutt & Cowen, 1983) . A better approach would have been a full Scatchard analysis over a range of radioligand concentrations. However, this investigation would have needed a very large number of animals since even the present single point binding determination required pooling of glands.
Iprindole has been reported to reduce cortical P-adrenoceptor binding (Wolfe et al., 1978) . Its failure to alter pineal P-adrenoceptor function, therefore, may reflect differences in the properties of pineal and cortical P-adrenoceptor synapses. Alternatively, since the reduction in P-adrenoceptor density following iprindole is usually somewhat less than that produced by DMI and amitriptyline (Sellinger-Bamette et al., 1980; Peroutka & Snyder, 1980) , it may be that any reduction in pineal 3-adrenoceptor density caused by iprindole is insufficient to result in a decreased functional response to isoprenaline. Our findings suggest that repeated administration of certain antidepressant treatments results in reduced pineal P-adrenoceptor responses. In the rat, plasma melatonin levels correlate closely with pineal melatonin synthesis (Wilkinson, Arendt, Bradtke & Ziegler, 1977) and it therefore seems possible that in man, measurement of plasma melatonin may provide a means of assessing alterations in P-adrenoceptor function during tricyclic antidepressant treatment.
